Category Archives: Parkinson’s Treatment

UCB Parkinsons Disease Treatment Market Scope Of The Report This report offers past, present as well as future analysis and estimates for the Parkinsons Disease Treatment market. The market estimates that are provided in the report are calculated through an exhaustive research methodology. Continue reading →

Parkinsons disease is a condition that causes the brain to become progressively more damaged over time, said the NHS. Continue reading →

INBRAIN Neuroelectronics, a spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2), the Barcelona Institute of Science and Technology (BIST) and ICREA, has received funding from Sabadell Asabys and Alta Life Sciences, as well as ICF and Finaves, which will allow the company to speed up the development of novel graphene-based implants to optimize the treatment of brain disorders, such as Parkinsons and epilepsy. INBRAIN Neuroelectronics was established in 2019 with the mission of developing brain-implants based on graphene technology for application in patients with epilepsy, Parkinsons, and other neuronal diseases. These smart devices, built around an innovative graphene electrode, will decode with high certainty neural signals from the brain and produce a therapeutic response adapted to the clinical condition of the specific patient. Continue reading →

Sinovac says early data show its Covid-19 vaccine generated Sinovac says early data show its Covid-19 vaccine generated immune responses Immunity to the coronavirus remains a mystery. Scientists are Immunity to the coronavirus remains a mystery. Continue reading →

COVID-19 Impact on Parkinsons Disease Treatment Market, Global Research Reports 2020-2021 In 2019, the global COVID-19 Impact on Parkinsons Disease Treatment Market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2021-2026. Continue reading →

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. Continue reading →

May 29, 2020 09:20 ET | Source: Minerva Neurosciences, Inc photo-release PANSS Negative Symptoms Factor Score (Marder) Change from Baseline (MMRM) (ITT Population) PSP Total Score Change from Baseline (MMRM) (ITT Population) WALTHAM, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the Phase 3 trial of roluperidone to treat negative symptoms in schizophrenia did not meet its primary (reduction in PANSS Marder Negative Symptoms Factor Score or NSFS) and key secondary (improvement in the Personal and Social Performance Scale Total Score or PSP) endpoints Continue reading →

Parkinsons disease is a neurodegenerative disorder that affects predominantly dopamine-producing (dopaminergic) neurons in a specific area of the brain called substantia nigra. Dopamine plays a vital role in regulating the movement of the body. Continue reading →

UCB Parkinsons Disease Treatment Market Competitive Analysis: In addition, the projections offered in this report were derived using proven research assumptions and methods. In this way, the Parkinsons Disease Treatment research study offers a collection of information and analysis for every facet of the Parkinsons Disease Treatment market such as technology, regional markets, applications and types. The Parkinsons Disease Treatment market report also offers some market presentations and illustrations that include pie charts, diagrams and charts that show the percentage of different strategies implemented by service providers in the Parkinsons Disease Treatment market Continue reading →

Parkinson's, Alzheimer's disease and other brain disorders - The neurological manifestations of COVID-19 | &nbspPhoto Credit:&nbspiStock Images New Delhi: Amidst the COVID 19 pandemic the whole nation is under lockdown, and looking at the current situation of increasing cases, the situation is likely to continue. While most of the professionals have been instructed to work from home, being devoid of a workplace ambience can cause depression and anxiety among many and those with pre-existing conditions may be at an added risk of health problems. We are very well aware that social distancing is the only proven measure to break the infection chain in the present situation, people also need to keep themselves engaged in fruitful activities in order to keep their mental health intact. Continue reading →